Completed PHASE4 INTERVENTIONAL 2-arm NCT00224081

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) (DRIVE)

Dialysis Patients' Response to IV Iron With Elevated Ferritin

Sponsor: Watson Pharmaceuticals

Conditions Anemia, Iron-Deficiency Hemodialysis Kidney Failure, Chronic

Updated 6 times since 2017 Last updated: Dec 8, 2015 Started: Sep 30, 2004 Primary completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00224081, this PHASE4 trial focuses on Anemia, Iron-Deficiency and Hemodialysis and remains completed. Sponsored by Watson Pharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Watson Pharmaceuticals

Data source: Watson Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Bakersfield, United States , Boston, United States , Brooklyn, United States , Chattanooga, United States , Columbia, United States , Crestwood, United States , Glendale, United States , Houston, United States , Kalamazoo, United States and 19 more locations